Nitric oxide donating anti-glaucoma drugs: advances and prospects

Glaucoma is a disease that causes irreversible blindness. Reducing intraocular pressure (IOP) is the main treatment at present. Nitric oxide (NO), an endogenous gas signaling molecule, can increase aqueous humor outflow facility, inhibit aqueous humor production thereby reducing IOP, as well as regu...

Full description

Saved in:
Bibliographic Details
Published inChinese journal of natural medicines Vol. 18; no. 4; pp. 275 - 283
Main Authors MAO, Yu-Jie, WU, Jian-Bing, YANG, Ze-Qiu, ZHANG, Yi-Hua, HUANG, Zhang-Jian
Format Journal Article
LanguageEnglish
Published China Elsevier B.V 01.04.2020
Subjects
Glaucoma
Glaucoma - drug therapy
Humans
Intraocular pressure
Intraocular Pressure - drug effects
Molecular Structure
Nitric oxide
Nitric Oxide - chemistry
Nitric Oxide - pharmacology
Prostaglandin analogues
Trabecular meshwork
Glaucoma
Trabecular meshwork
Nitric oxide
Prostaglandin analogues
Intraocular pressure
Online AccessGet full text

Cover

More Information
Summary:Glaucoma is a disease that causes irreversible blindness. Reducing intraocular pressure (IOP) is the main treatment at present. Nitric oxide (NO), an endogenous gas signaling molecule, can increase aqueous humor outflow facility, inhibit aqueous humor production thereby reducing IOP, as well as regulate eye blood flow and protect the optic nerve. Therefore, NO donating anti-glaucoma drugs have broad research prospects. In this review, we summarize NO-mediated therapy for glaucoma, and the state of the art of some NO donating molecules, including latanoprostene bunod in market and some other candidate compounds, for the intervention of glaucoma, as well as prospects and challenges ahead in this field.
ISSN:1875-5364
1875-5364
DOI:10.1016/S1875-5364(20)30035-2